Acute promyelocytic leukemia · 10 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Arsenic trioxide, ATRA, Gemtuzumab ozogamicin Variant #02 | — | R 241 362 | — | — | — | — | — | — |
Arsenic trioxide and ATRA Variant #03 | — | R 231 223 | 56d | — | — | — | — | 1 |
Arsenic trioxide, ATRA, Idarubicin Variant #01 | — | R 149 299 | 36d | — | — | — | — | — |
ATRA and Idarubicin Variant #01 | — | R 66 298 | 90d | — | — | — | — | — |
ATRA, Cytarabine, Daunorubicin Variant #01 | — | R 56 370 | 90d | — | — | — | — | — |
ATRA and Daunorubicin Variant #01 | — | R 55 345 | 90d | — | — | — | — | — |
ATRA monotherapy Variant #01 | — | R 44 112 | — | — | — | — | — | — |
ATRA, Cytarabine, Idarubicin Variant #01 | — | R 18 155 | — | — | — | — | — | — |
ADE and ATRA Variant #01 | — | R 13 060 | — | — | — | — | — | — |
Arsenic trioxide monotherapy N/A - intrathecal component | — | R 0 | — | — | — | — | — | — |
10 of 10 regimens shown